Kenya has invited firms through a global tender to bid for the construction of a Covid-19 vaccine plant as it enters the homestretch on manufacturing the jab locally.
The State is seeking to recruit a consultant and a firm to design, build, commission and maintain a fully-fledged vaccine manufacturing facility.
The tender has been floated through an advertisement by the Kenya BioVax Institute, a State-owned commercial and manufacturing firm.
“To achieve this objective, the Government of Kenya desires to recruit a GMP consultant and a firm to design-build-commission-maintain a fully-fledged vaccine manufacturing facility,” a public notice, signed by the director-general Kenya BioVax Institute states.
The floating of the tender comes barely three months after President Uhuru Kenyatta announced that Kenya had started building a filling plant for the Covid-19 vaccines by April ahead of a fully-fledged manufacturing capability by 2024.
“As the first step towards this goal, we have established the Kenya BioVax Limited as a venture that would locally produce anti-Covid-19 vaccines,” said President Uhuru Kenyatta.
“I, therefore, directed the Ministry of Health to operationalise the company,” he said.